Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

4.040 +0.080 (+2.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,685,573
Open 3.990
Bid (Size) 4.040 (200)
Ask (Size) 4.050 (100)
Prev. Close 3.960
Today's Range 3.910 - 4.145
52wk Range 1.639 - 5.630
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments ↗
Via MarketBeat
News headline image
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 ↗
If you decide to invest in this company, it's probably best to start small. 
Via The Motley Fool

Performance

YTD
+60.3%
+60.3%
1 Month
+57.2%
+57.2%
3 Month
+87.0%
+87.0%
6 Month
+78.0%
+78.0%
1 Year
+8.0%
+8.0%

More News

Read More
News headline image
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? ↗
Via Stocktwits
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Reports Q4 Revenue Beat and Strong Clinical Progress ↗
Via Chartmill
News headline image
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why ↗
Via Stocktwits
Topics Earnings
Curious about the most active stocks on Tuesday? ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Iovance (IOVA) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Why Did IOVA Stock Gain Pre-Market Today? ↗
Via Stocktwits
News headline image
Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits ↗
Via The Motley Fool
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
IOVA Shares Jump 8% — What’s Retail Expecting? ↗
Via Stocktwits
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗
Via The Motley Fool
Topics Death
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗
Via The Motley Fool
News headline image
Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Biotech Valuations Rise as New Clinical Platforms Show Progress
Via Investor Brand Network

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 4.040
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 03/16/26 04:00 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 1.23B
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.